Yumanity Therapeutics, Inc. (NASDAQ:YMTX) Short Interest Update

Yumanity Therapeutics, Inc. (NASDAQ:YMTXGet Rating) was the target of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 117,800 shares, a drop of 14.6% from the May 15th total of 138,000 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.5% of the company’s shares are sold short.

Large investors have recently made changes to their positions in the company. Morgan Stanley acquired a new stake in Yumanity Therapeutics in the 2nd quarter valued at $29,000. Jane Street Group LLC bought a new stake in Yumanity Therapeutics in the first quarter valued at about $35,000. Virtu Financial LLC bought a new stake in Yumanity Therapeutics in the fourth quarter valued at about $48,000. Bank of America Corp DE increased its holdings in shares of Yumanity Therapeutics by 88,425.0% in the second quarter. Bank of America Corp DE now owns 7,082 shares of the company’s stock worth $83,000 after acquiring an additional 7,074 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Yumanity Therapeutics by 29.2% in the fourth quarter. Geode Capital Management LLC now owns 49,888 shares of the company’s stock worth $147,000 after acquiring an additional 11,275 shares in the last quarter. 27.71% of the stock is currently owned by institutional investors.

Shares of NASDAQ YMTX opened at $1.57 on Friday. Yumanity Therapeutics has a one year low of $0.95 and a one year high of $13.90. The firm has a market capitalization of $17.02 million, a PE ratio of -0.37 and a beta of 0.89. The business has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.85.

Yumanity Therapeutics (NASDAQ:YMTXGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.22). Yumanity Therapeutics had a negative net margin of 798.73% and a negative return on equity of 162.54%. The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $1.50 million. On average, equities research analysts forecast that Yumanity Therapeutics will post -4.55 EPS for the current fiscal year.

About Yumanity Therapeutics (Get Rating)

Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.